Finally, we did not evaluate potential known interactions between androgen receptor blockade and downstream compounds, i.e., cAMP/PKA signaling, which may be involved in alternative pathways underlying castration-recurrent prostate cancer [64]. This evidence concerns the gene AR and prostate cancer.